Cardioprotective effect occurred in patients independently of blood sugar control
Boehringer to progress R&D partnership that began last year
Drugs improve on existing medicines from Boehringer and Roche.
Label gives guidance in use when restoring normal heart rhythm
BI developing combinations with its own checkpoint inhibitors
BI boosted by new diabetes and respiratory drugs.
AZ hopes data will boost sales of its Farxiga.
Balancing innovation and huge unmet patient need with burgeoning cost constraints.
Lilly/Boehringer gain further advantage in US diabetes market.